Ab­b­Vie antes up $225M in cash to buy in­to the Alzheimer's plat­form at Alec­tor

For well over a decade now, the ma­jor fo­cus in Alzheimer’s R&D has been con­cen­trat­ing heav­i­ly — though not ex­clu­sive­ly — on the tan­gles of tox­ic amy­loid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA